268 related articles for article (PubMed ID: 32394765)
1. Switching biologics in psoriasis - practical guidance and evidence to support.
Tsai YC; Tsai TF
Expert Rev Clin Pharmacol; 2020 May; 13(5):493-503. PubMed ID: 32394765
[TBL] [Abstract][Full Text] [Related]
2. Biologics in pediatric psoriasis - efficacy and safety.
Dogra S; Mahajan R
Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
[TBL] [Abstract][Full Text] [Related]
3. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.
Hsu SH; Tsai TF
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):211-232. PubMed ID: 32167790
[No Abstract] [Full Text] [Related]
5. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.
Hu Y; Chen Z; Gong Y; Shi Y
Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053
[TBL] [Abstract][Full Text] [Related]
6. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
7. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
[No Abstract] [Full Text] [Related]
8. Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent.
Hjalte F; Steen Carlsson K; Schmitt-Egenolf M
Dermatology; 2015; 230(4):347-53. PubMed ID: 25721571
[TBL] [Abstract][Full Text] [Related]
9. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F;
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473
[TBL] [Abstract][Full Text] [Related]
10. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience.
Özkur E; Kıvanç Altunay İ; Oğuz Topal İ; Aytekin S; Topaloğlu Demir F; Özkök Akbulut T; Kara Polat A; Karadağ AS
Dermatology; 2021; 237(1):22-30. PubMed ID: 31865339
[TBL] [Abstract][Full Text] [Related]
11. Switching of biologics in psoriasis: Reasons and results.
Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
[TBL] [Abstract][Full Text] [Related]
12. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
13. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
Kolli SS; Kepley AL; Cline A; Feldman SR
Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
15. Biologics switch in psoriasis.
Wang TS; Tsai TF
Immunotherapy; 2019 Apr; 11(6):531-541. PubMed ID: 31135243
[No Abstract] [Full Text] [Related]
16. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
17. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea.
Shin JO; Shin BS; Bae KN; Shin K; Kim HS; Ko HC; Kim MB; Kim B
Indian J Dermatol Venereol Leprol; 2023; 89(6):928. PubMed ID: 37317715
[TBL] [Abstract][Full Text] [Related]
18. Switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group.
Ganzetti G; Campanati A; Bettacchi A; Brandozzi G; Brisigotti V; Bugatti L; Cataldi I; Filosa G; Giacchetti A; Lemme G; Morresi L; Nicolini M; Postacchini V; Ricotti G; Rosa L; Simonacci M; Offidani A
G Ital Dermatol Venereol; 2018 Feb; 153(1):5-10. PubMed ID: 27845513
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
[TBL] [Abstract][Full Text] [Related]
20. When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.
Damiani G; Conic RRZ; de Vita V; Costanzo A; Regazzini R; Pigatto PDM; Bragazzi NL; Pacifico A; Malagoli P
Dermatol Ther; 2019 Mar; 32(2):e12793. PubMed ID: 30515970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]